Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib

In its latest cross-border in-licensing deal, Zai gained territorial rights to yet another targeted cancer therapy via a deal with Turning Point for repotrectinib, which is in a pivotal trial that could lead to approvals in both lung cancer and a tissue-agnostic indication.

Zai Lab Ltd. (NASDAQ:ZLAB) will pay $25 million up front to gain rights in Greater China to repotrectinib, a small molecule

Read the full 630 word article

How to gain access

Continue reading with a
two-week free trial.